Results 71 to 80 of about 29,271 (207)

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

American Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, Marc Michel, Carlo Visco, Michael Fillitz, George Kannourakis, Maria Bruna Greve, Moritz Kleemiss, Johan Cid, Andrea Patriarca, Laura Pavan, Arbana Dizdari, Nilla Maschio, Antonella Sau, Cinzia Bitetti, Riccardo Mario Colombo, Luigi Curreli, Dorela Lame, Uros Markovic, Fabrizio Pappagallo, Giacinto Luca Pedone, Davide Rapezzi, Vincenzo Sammartano, Nicola Tumedei, Antonio Giovanni Solimando, Jalink Marit, Luana Fianchi, Jahanzaib Khwaja, Antonio De Vivo, Francesco Lanza, Fabrizio Vianello, Esther N. Oliva, Catherine Broome, Francesco Passamonti, Ulrich Jaeger, Bernd Jilma, Guillaume Moulis, Wilma Barcellini   +38 more
wiley   +1 more source

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. [PDF]

, 2017
ROR1 (receptor tyrosine kinase-like orphan receptor 1) is a conserved, oncoembryonic surface antigen expressed in chronic lymphocytic leukemia (CLL).
A Butrym, A Stacchini, AH Daneshmanesh, AM Brunati, B Cui, C Scielzo, C Scielzo, C Wilson, D Kitamura, DA Dehring, E Roszmusz, E Ten Hacken, E ten Hacken, ES Witze, F Frezzato, GF Widhopf II, HE Broome, J Skokowa, J Yu, J Yu, JA Burger, JA Di Paolo, JJ Hao, K Alexandropoulos, K Kurokawa, M Lettau, M Muzio, M Rodriguez-Niedenfuhr, MY Choi, N Martinez-Quiles, P Masiakowski, P Masiakowski, PJ Cavnar, S Baskar, S Mukherjee, T Fukuda, T Uruno, TS Gomez, WC Forrester, WC Forrester, X Qi, Y Suzuki, Y Takemoto, Y Yamanashi, YK Xu, Z Weng   +45 more
core   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions

Haematologica, 2019
While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two ...
Jennifer Series, Cédric Garcia, Marie Levade, Julien Viaud, Pierre Sié, Loïc Ysebaert, Bernard Payrastre   +6 more
doaj   +1 more source

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse

Biomarker Research, 2020
Background Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations.
Sarah Cadot, Carine Valle, Marie Tosolini, Frederic Pont, Laetitia Largeaud, Camille Laurent, Jean Jacques Fournie, Loic Ysebaert, Anne Quillet-Mary   +8 more
doaj   +1 more source

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results

Blood Cancer Journal, 2021
Ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL). This drug irreversibly inhibits Bruton tyrosine kinase (BTK) by covalently binding to the C481 residue in the BTK kinase domain.
Natalia Timofeeva, Varsha Gandhi
doaj   +1 more source

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study. [PDF]

Cancer
Abstract Background Real‐world data are an essential complement to clinical trials. This is particularly true for chronic lymphocytic leukemia, where five first‐line options have never been directly compared. Methods The authors present the results of a national multicenter real‐world study focusing on treatment choices in frontline chronic lymphocytic
Coste A, Sritharan N, Lok A, Tomowiak C, Ferrant E, Clavert A, Roos-Weil D, Bouclet F, Caillet A, Croizier C, Stocker N, Tchernonog E, Feugier P, Santagostino A, Hivert B, Michallet AS, De Guibert S, Lara D, Waultier-Rascalou A, Merabet F, Durand A, Bussot L, Laribi K, Dilhuydy MS, Lévy V, Quinquenel A.   +25 more
europepmc   +2 more sources

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib [PDF]

, 2017
The Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side-effects of ibrutinib.
Appleby, Niamh, Bruce, David, Bye, Alex P., Desborough, Michael J., Gibbins, Jon M., Hildyard, Catherine A. T., Hughes, Craig E., Kriek, Neline, Nock, Sophie H., Sage, Tanya, Unsworth, Amanda J.   +10 more
core   +2 more sources

Modular Rh‐Catalyzed Synthesis and Biological Profiling of Diverse Pentafluorobenzenesulfonamide Reactive Fragments

Chemistry – A European Journal, EarlyView.
A modular Rh‐catalyzed synthetic approach enabled the preparation of diverse reactive fragments from available substrates. The reactive fragments modified Aurora A kinase via several distinct modification reaction classes. In a complex biological environment, the constellation of modified proteins depended critically on the reactive fragment structure.
Julian Chesti, Jennifer A. Miles, George J. Wade, Scott Grossman, George W. Preston, Richard Bayliss, Stuart L. Warriner, Megan H. Wright, Adam Nelson   +8 more
wiley   +1 more source